Egetis to present Emcitate clinical data for MCT8 deficiency in September 2026
Egetis Therapeutics AB (EGTX) said clinical data for Emcitate (tiratricol) in the treatment of MCT8 deficiency will be presented at the 47th Annual Meeting of the European…
Stockholm, Sweden, September 4, 2026.
Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced that clinical data relating to Emcitate® (tiratricol) for the treatment of MCT8 deficiency will be presented at the upcoming 47th Annual Meeting of the European…